» Articles » PMID: 30691196

Novel Approach for the Search for Chemical Scaffolds with Dual Activity with Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptor-A Perspective for the Treatment of Neurodegenerative Disorders

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2019 Jan 30
PMID 30691196
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative disorders, including Alzheimer's disease, belong to the group of the most difficult and challenging conditions with very limited treatment options. Attempts to find new drugs in most cases fail at the clinical stage. New tactics to develop better drug candidates to manage these diseases are urgently needed. It is evident that better understanding of the neurodegeneration process is required and targeting multiple receptors may be essential. Herein, we present a novel approach, searching for dual active compounds interacting with acetylcholinesterase (AChE) and the α7 nicotinic acetylcholine receptor (nAChR) using computational chemistry methods including homology modelling and high throughput virtual screening. Activities of identified hits were evaluated at the two targets using the colorimetric method of Ellman and two-electrode voltage-clamp electrophysiology, respectively. Out of 87,250 compounds from a ZINC database of natural products and their derivatives, we identified two compounds, and , with dual activity and balanced IC values of 10 and 5 µM at AChE, and 34 and 14 µM at α7 nAChR, respectively. This is the first report presenting successful use of virtual screening in finding compounds with dual mode of action inhibiting both the AChE enzyme and the α7 nAChR and shows that computational methods can be a valuable tool in the early lead discovery process.

Citing Articles

Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials.

Park K, Gao Y Front Neurosci. 2024; 18:1481390.

PMID: 39513042 PMC: 11541110. DOI: 10.3389/fnins.2024.1481390.


Targeting ion channels with ultra-large library screening for hit discovery.

Melancon K, Pliushcheuskaya P, Meiler J, Kunze G Front Mol Neurosci. 2024; 16:1336004.

PMID: 38249296 PMC: 10796734. DOI: 10.3389/fnmol.2023.1336004.


Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs.

Dorahy G, Chen J, Balle T Molecules. 2023; 28(3).

PMID: 36770990 PMC: 9921936. DOI: 10.3390/molecules28031324.


Using a Parkinson's Disease Model to Assess Disease Progression and Therapy Efficiency.

Hughes S, van Dop M, Kolsters N, van de Klashorst D, Pogosova A, Rijs A Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631338 PMC: 9143865. DOI: 10.3390/ph15050512.


Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer's Disease.

Shityakov S, Skorb E, Forster C, Dandekar T Front Chem. 2021; 9:736509.

PMID: 34751244 PMC: 8571023. DOI: 10.3389/fchem.2021.736509.


References
1.
Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

2.
Notredame C, Higgins D, Heringa J . T-Coffee: A novel method for fast and accurate multiple sequence alignment. J Mol Biol. 2000; 302(1):205-17. DOI: 10.1006/jmbi.2000.4042. View

3.
Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

4.
Jorgensen W, Duffy E . Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002; 54(3):355-66. DOI: 10.1016/s0169-409x(02)00008-x. View

5.
Hameg A, Bayle F, Nuss P, Dupuis P, Garay R, Dib M . Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003; 65(3):435-40. DOI: 10.1016/s0006-2952(02)01515-0. View